Fund raising, which began when aHUSUK still existed, has been put to use to help fund research which may improve the aHUS diagnosis process. Readers of this website may have…
We’re pleased to feature this interview with Dr Brad Lewis, Medical Director of Machaon Diagnostics. A hematologist with background in biochemistry and focus on thrombosis and hemostasis, Dr Lewis lectures…
Ravulizumab is eculizumab, Carsten. They work the same way. It is the same monoclonal antibody. It has just been modified in a couple of places so that it is effective…
When Jeff, the producer of these awareness day videos, suggested that "questions" should be the theme of this years' RDD Video I was surprised. Surprised because it had been five…
Article No. 457 Yet another article about the outcome of withdrawal of eculizumab treatment has appeared. It is not about a controlled trial of patients selected to test withdrawal of…
People with atypical HUS need urgent care during periods of disease activity, with treatment when needed for as long as needed. But how is such optimal care duration determined, and…
Atypical HUS Research – What’s New? The aHUS Alliance Global Action team has created a virtual ‘library’ of publications that are aHUS-specific and are categorized by topics such as diagnosis, treatment, genetics, thrombotic microangiopathy (TMA), complement, transplant, pregnancy, and more.
Article No. 442 23 June 2021 Today NICE ( The National Institute for Health and Care Excellence) concluded its evaluation of ravulizumab for treating aHUS by publishing its Final Guidance…